Dexcom

At a glance

Dexcom reported 2025 revenue of $4.66B, up 15.6% from $4.03B in 2024. Over 4 years since 2021 ($2.45B), that is growth of about 17.5% a year. Operating margin was 19.6%, up from 10.9% in 2021. 2025 was the highest revenue year in this period.

In the last 12 months 10 insiders reported 1 open-market purchase ($1M) and 26 sales ($13M). All of the sales were made under pre-arranged 10b5-1 trading plans. The largest was a sale of $2.4M by Executive Chair Kevin R Sayer on Aug 24, 2026. Net, insiders were sellers of $12M.

Dexcom filed 12 current reports (Form 8-K) in the last 12 months, most often for results of operations (5), officer or director change (5), shareholder vote results (1) and regulation fd disclosure (1). The latest officer or director change was reported on Sep 14, 2026.

3 of the 20 investors tracked here held Dexcom at the last quarter end, worth $181.3M combined. It is the largest weight for Renaissance Technologies (0.2% of its portfolio), followed by Bridgewater Associates (0.1%). Added: Renaissance Technologies, Bridgewater Associates and National Pension Service (Korea).

Annual results

Fiscal year ends Dec 31 · incorporated in DE

Tracked investors holding (13F)

Weight is the share of each investor's portfolio, as of the quarter end.